ReviewInfection2024
Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.
Review in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Contezolid in the Treatment of Multidrug-Resistant Tuberculous Meningitis: A Case Report.Clinical case reports · 2026Article
- Contezolid and polymyxin B nonapeptide combination reveals antibacterial synergy against multidrug-resistant Acinetobacter baumannii strains.BMC microbiology · 2026Article
- Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Effective sequential therapy of linezolid and contezolid against HA-MRSA-induced necrotizing pneumonia in a 95-year-old patient with multimorbidity.BMC infectious diseases · 2025Article
- Efficacy and safety of contezolid in the treatment of Gram-positive bacterial infections in patients with hematological malignancies: a retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- In Vitro Antimicrobial Activity of Contezolid AgainstMicroorganisms · 2025Article
- Contezolid, a novel oxazolidinone antibiotic, acts as a potential anti-inflammatory agent.The Journal of antibiotics · 2025Article
- Contezolid for the Super-Elderly: Balancing Efficacy and Safety Through Pharmacokinetic Insights.Clinical interventions in aging · 2025Observational
- LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring.Drug design, development and therapy · 2025Article
- β-tricalcium phosphate/calcium sulfate loaded with contezolid acefosamil (MRX-4) for antimicrobial potency, prevention and killing efficacy of MRSA biofilm.Frontiers in pharmacology · 2025Article
- Deciphering the Intricate Interplay in the Framework of Antibiotic-Drug Interactions: A Narrative Review.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe principal objective of this project was to review and thoroughly examine the chemical characteristics, pharmacological activity, and quantification methods associated with contezolid.
methodsThe article was based on published and ongoing preclinical and clinical studies on the application of contezolid. These studies included experiments on the physicochemical properties of contezolid, in vitro antimicrobial research, in vivo antimicrobial research, and clinical trials in various phases. There were no date restrictions on these studies.
resultsIn June 2021, contezolid was approved for treating complicated skin and soft tissue infections. The structural modification of contezolid has resulted in better efficacy compared to linezolid. It inhibits bacterial growth by preventing the production of the functional 70S initiation complex required to translate bacterial proteins. The current evidence has indicated a substantial decline in myelosuppression and monoamine oxidase inhibition without impairing its antibacterial properties. Contezolid was found to have a more significant safety profile and to be metabolised by flavin monooxygenase 5, reducing the risk of harmful effects due to drug-drug interactions. Adjusting doses is unnecessary for patients with mild to moderate renal or hepatic insufficiency.
conclusionAs an oral oxazolidinone antimicrobial agent, contezolid is effective against multi-drug resistant Gram-positive bacteria. The introduction of contezolid provided a new clinical option.
Indexed as
Identifiers
38717734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.